Wave Life Sciences Reports Financial Results and Strategic Developments in Recent 10-K Filing
Wave Life Sciences Ltd., a clinical-stage biotechnology company, disclosed its financial performance and strategic updates in its recent 10-K filing. The company reported collaboration revenue of $42.7 million for the year ended December 31, 2025, a decrease from $108.3 million in 2024 and $113.3 million in 2023. This decrease was primarily due to the termination of the Takeda Collaboration Agreement in October 2024, which led to the recognition of the remainder of the deferred revenue related to the research and development services, as well as the license related to the HD program. The company's net loss for 2025 was $204.4 million, compared to $97.0 million in 2024 and $57.5 million in 2023.
The company's research and development expenses increased to $182.8 million in 2025 from $159.7 million in 2024, driven by increased investment in the INHBE and DMD programs, as well as increased compensation and facilities-related expenses. General and administrative expenses also rose to $75.3 million in 2025 from $59.0 million in 2024, primarily due to increases in compensation and administrative expenses. As of December 31, 2025, Wave Life Sciences had cash and cash equivalents of $602.1 million, which the company believes will be sufficient to fund operations for at least the next 12 months.
Key operational developments highlighted in the filing include the ongoing INLIGHT Phase 1 clinical trial for WVE-007 in individuals living with obesity, with interim data showing improved body composition and Activin E reductions. The RestorAATion-2 clinical trial for WVE-006 in AATD patients is fully enrolled through the 600 mg cohort, with data from the 400 mg multidose cohort expected in the first quarter of 2026. The company also expects to file a clinical trial application for WVE-008 in 2026, which is for PNPLA3 I148M liver disease. The company plans to file a New Drug Application in 2026 to support accelerated approval of WVE-N531 with monthly dosing.
Looking ahead, Wave Life Sciences anticipates delivering six-month follow-up data from the 240 mg cohort and three-month follow-up data from the 400 mg cohort of the INLIGHT clinical trial in the first quarter of 2026. The company also expects to initiate the Phase 2a multidose portion of the INLIGHT clinical trial in the first half of 2026, as well as new clinical trials evaluating WVE-007 as an incretin add-on and as post-incretin maintenance in 2026. In February 2026, the company announced it was accelerating regulatory engagement for WVE-006, and expects to receive regulatory feedback on a potential accelerated approval pathway mid-2026. The company expects to deliver data from the 400 mg multidose cohort of the RestorAATion-2 clinical trial in the first quarter of 2026, and single and multidose data from the 600 mg cohort in 2026.
About Wave Life Sciences Ltd.
Wave Life Sciences Ltd. is a biotechnology company specializing in RNA-based therapeutics using its proprietary PRISM platform. It develops innovative oligonucleotide medicines across modalities like RNA editing, splicing, and silencing to treat rare and common diseases. Its pipeline includes programs for obesity, genetic liver disorders, muscular dystrophy, and neurodegenerative diseases, leveraging chemistry innovations for targeted, durable, and delivery-efficient RNA therapies.
About 10-K Filings
A 10-K form is a comprehensive annual report that public companies in the United States must file with the SEC, providing a detailed overview of the company's financial condition, performance, and business strategies.
Key points about the 10-K:
- Frequency: Filed annually, typically within 60 to 90 days after the end of the company's fiscal year.
-
Content: It includes:
- Detailed financial statements audited by an independent accounting firm
- Management's Discussion and Analysis (MD&A) of financial condition and results
- Description of the company's business, properties, and legal proceedings
- Risk factors and market risks
- Executive compensation and corporate governance information
- Importance: Considered the most comprehensive and important document a public company files with the SEC.
- Length: Often exceeds 100 pages due to its extensive and detailed nature.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.